CGON Stock Forecast & Price Target

CG Oncology is supported by a lead asset, cretostimogene grenadenorepvec, that has shown differentiated complete response activity, a clean safety profile, and potential to benefit from the ongoing global BCG shortage, which could drive adoption across intermediate- and high-risk NMIBC. The near-term PIVOT-006 readout is a major catalyst, with prior control-arm data and accumulated events suggesting the trial may validate the drug’s effect and support a meaningful IR-NMIBC expansion with an estimated $1.2B peak sales opportunity. Financially, the company reported $1B in cash and cash equivalents, enough to fund operations through 2029, while BLA completion remains on track for 4Q26 and a broad pipeline of 2026 updates could further de-risk the story.

CG Oncology is a highly concentrated late-stage biopharmaceutical company whose valuation depends almost entirely on cretostimogene grenadenorepvec, leaving it exposed to single-asset risk and any disappointing data in its IR/HRNMIBC programs. The key fundamental concern is that clinical, regulatory, and commercial execution risk remains elevated, with the possibility that trials fail to show meaningful efficacy, approvals are delayed, or competing products with greater resources pressure adoption. Financially, the company may also need additional equity financing to finish development, while its market opportunity could be challenged by TAR-200 share accrual dynamics driven by reimbursement factors.